Neurol. praxi. 2025;26(4):320-323 | DOI: 10.36290/neu.2025.003

Patients with myasthenia gravis as seen by a urologist

MUDr. Eva Burešová, Ph.D.
Urologická klinika LF UP a FN Olomouc

Myasthenia gravis is a neurological autoimmune disease characterized by muscle fatigue. There are two clinical forms: ocular and generalized. The disease should be both diagnosed and treated in myasthenia centres. Myasthenia patients tend to have urinary tract symptoms; therefore, for a urologist, it is important to recognize the symptoms of myasthenia gravis that has not yet been diagnosed. In the treatment of urological diseases in these patients, avoid medication that is contraindicated and/or could lead to worsening of myasthenia symptoms.

Keywords: myasthenia gravis, acetylcholine receptor, antimuscarinic drugs.

Received: July 9, 2024; Revised: December 30, 2024; Accepted: January 16, 2025; Prepublished online: January 16, 2025; Published: September 29, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Burešová E. Patients with myasthenia gravis as seen by a urologist. Neurol. praxi. 2025;26(4):320-323. doi: 10.36290/neu.2025.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 29.9.2026

    References

    1. Antoniou A, Mendez Rodrigues J, Comi N. Successful treatment of urodynamic detrusor over-activity in a young patient with myasthenia gravis using pretibial nerve stimulation with follow-up to two years. JRSM Open. 2016;7(8):205-227. Go to original source... Go to PubMed...
    2. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843-2854. Go to original source... Go to PubMed...
    3. Dixon PJ, Christmas TJ, Chapple CR. Stress incontinence due to pelvic floor muscle involvement in limb-girdle muscular dystrophy. Br J Urol. 1990;65:653-4. Go to original source... Go to PubMed...
    4. Grob D. Course and management of myasthenia gravis. J Am Med Assoc. 1993;153:529-532. Go to original source... Go to PubMed...
    5. Huijbers MG, Lipka AF, Plomp JJ, et al. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. J Intern Med. 2014;275(1):12-26. Go to original source... Go to PubMed...
    6. Joles JA, Rijnberk A, van den Brom WE, et al. Studies on the mechanism of polyuria induced by cortisol excess in the dog. Vet Q. 1980;2:199-205. Go to original source... Go to PubMed...
    7. Marouani I, Kraoua I, Benrhouma H, et al. Seronegative myasthenia gravis with bladder dysfunction. Rev Neurol. 2012;168:299-300. Go to original source... Go to PubMed...
    8. Obara K, Kobayashi Y, Chino D, et al. Effects of distigmine on electrical field stimulation-induced contraction of mouse urinary bladder smooth muscles. Pharmacology. 2017;99(3-4):106-13. Go to original source... Go to PubMed...
    9. Piťha J. Farmakologické ovlivnění nervosvalového přenosu u myasthenia gravis. Remedia. 2004;14(6):485-494.
    10. Riggs AJ, Riggs JE, John A. Simpson and myasthenia gravis: the role of analogy in science. Neurology. 2004;62(3):465-7. Go to original source... Go to PubMed...
    11. Sakakibara R, Hamano S, Uchiyama T, et al. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int. 2005;74:44-50. Go to original source... Go to PubMed...
    12. Sakakibara R, Ito T, Uchiyama T, et al. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int. 2008;81:335-9. Go to original source... Go to PubMed...
    13. Sakakibara R, Panicker J, Fowler CJ, et al. Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol. 2014;21:33-8. Go to original source... Go to PubMed...
    14. Sakakibara R, Uchiyama T, Tamura N,etal. Urinary retention and sympathetic sphincter obstruction in axonal Guillain-Barré syndrome. Muscle Nerve. 2007;35:111-5. Go to original source... Go to PubMed...
    15. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014;175(3):408-418. Go to original source... Go to PubMed...
    16. Staskin D, Frankel J, Varano S, et al: International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204: 316. Go to original source... Go to PubMed...
    17. Tateno F, Sakakibara R, Aiba Y. Lower Urinary Tract Symptoms in Myasthenia Gravis. Case Rep Neurol. 2021;13(2):490-498. Go to original source... Go to PubMed...
    18. www.mysteniagravis.cz.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.